Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2020-04-06
DOI
10.1080/17474086.2020.1746639
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology
- (2019) Istvan M. Majer et al. PHARMACOECONOMICS
- Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)
- (2019) Philippe Moreau et al. LEUKEMIA
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
- (2017) Andrzej J. Jakubowiak et al. Expert Review of Hematology
- Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
- (2016) Christopher Jackson et al. MEDICAL DECISION MAKING
- Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
- (2016) Andrzej J. Jakubowiak et al. JOURNAL OF MEDICAL ECONOMICS
- Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials
- (2014) Joseph M. Unger et al. JNCI-Journal of the National Cancer Institute
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
- (2013) Robert Z. Orlowski SEMINARS IN ONCOLOGY
- Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
- (2012) Andrzej Jakubowiak SEMINARS IN HEMATOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib
- (2011) Jörgen Möller et al. JOURNAL OF MEDICAL ECONOMICS
- The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective
- (2010) John Hornberger et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
- (2009) Bruce E. Hillner et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma
- (2009) Marc S Raab et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started